scholarly journals The Fusion Gene Landscape in Taiwanese Patients with Non-Small Cell Lung Cancer

Cancers ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 1343
Author(s):  
Ya-Sian Chang ◽  
Siang-Jyun Tu ◽  
Ju-Chen Yen ◽  
Ya-Ting Lee ◽  
Hsin-Yuan Fang ◽  
...  

Background: Analyzing fusion gene transcripts may yield an effective approach for selecting cancer treatments. However, few comprehensive analyses of fusions in non-small cell lung cancer (NSCLC) patients have been performed. Methods: We enrolled 54 patients with NSCLC, and performed RNA-sequencing (RNA-Seq). STAR (Spliced Transcripts Alignment to a Reference)-Fusion was used to identify fusions. Results: Of the 218 fusions discovered, 24 had been reported and the rest were novel. Three fusions had the highest occurrence rates. After integrating our gene expression and fusion data, we found that samples harboring fusions containing ASXL1, CACNA1A, EEF1A1, and RET also exhibited increased expression of these genes. We then searched for mutations and fusions in cancer driver genes in each sample and found that nine patients carried both mutations and fusions in cancer driver genes. Furthermore, we found a trend for mutual exclusivity between gene fusions and mutations in the same gene, with the exception of DMD, and we found that EGFR mutations are associated with the number of fusion genes. Finally, we identified kinase gene fusions, and potentially druggable fusions, which may play roles in lung cancer therapy. Conclusion: The clinical use of RNA-Seq for detecting driver fusion genes may play an important role in the treatment of lung cancer.

Cancers ◽  
2021 ◽  
Vol 13 (1) ◽  
pp. 139
Author(s):  
Caterina De Luca ◽  
Francesco Pepe ◽  
Antonino Iaccarino ◽  
Pasquale Pisapia ◽  
Luisella Righi ◽  
...  

Gene fusions represent novel predictive biomarkers for advanced non-small cell lung cancer (NSCLC). In this study, we validated a narrow NGS gene panel able to cover therapeutically-relevant gene fusions and splicing events in advanced-stage NSCLC patients. To this aim, we first assessed minimal complementary DNA (cDNA) input and the limit of detection (LoD) in different cell lines. Then, to evaluate the feasibility of applying our panel to routine clinical samples, we retrospectively selected archived lung adenocarcinoma histological and cytological (cell blocks) samples. Overall, our SiRe RNA fusion panel was able to detect all fusions and a splicing event harbored in a RNA pool diluted up to 2 ng/µL. It also successfully analyzed 46 (95.8%) out of 48 samples. Among these, 43 (93.5%) out of 46 samples reproduced the same results as those obtained with conventional techniques. Intriguingly, the three discordant results were confirmed by a CE-IVD automated real-time polymerase chain reaction (RT-PCR) analysis (Easy PGX platform, Diatech Pharmacogenetics, Jesi, Italy). Based on these findings, we conclude that our new SiRe RNA fusion panel is a valid and robust tool for the detection of clinically relevant gene fusions and splicing events in advanced NSCLC.


2020 ◽  
Vol 3 ◽  
pp. 14-14
Author(s):  
Alessandro Russo ◽  
Ana Rita Lopes ◽  
Katherine Scilla ◽  
Ranee Mehra ◽  
Vincenzo Adamo ◽  
...  

2020 ◽  
Vol 160 (2) ◽  
pp. e71-e79 ◽  
Author(s):  
Richard Zheng ◽  
Qian Shen ◽  
Stacey Mardekian ◽  
Charalambos Solomides ◽  
Zi-Xuan Wang ◽  
...  

2019 ◽  
Vol 110 (8) ◽  
pp. 2348-2356 ◽  
Author(s):  
Hao Chen ◽  
Wei Chong ◽  
Changcai Teng ◽  
Yueliang Yao ◽  
Xin Wang ◽  
...  

2014 ◽  
Vol 52 (1) ◽  
pp. 49-56 ◽  
Author(s):  
Makoto Kobayashi ◽  
Tomohiro Sakakibara ◽  
Akira Inoue ◽  
Tatsuro Fukuhara ◽  
Hironobu Sasano ◽  
...  

2020 ◽  
Vol 11 (6) ◽  
pp. 1525-1531 ◽  
Author(s):  
Shan Lu ◽  
Can Lu ◽  
YuXuan Xiao ◽  
Wei Zhu ◽  
QiuYan He ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document